Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 18/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27008691 | 0.86 | OGA (0.66) | OGAKMT2A | |
| SCHEMBL29057509 | 0.73 | OGA (0.48) | OGAMEN1KMT2A | |
| SCHEMBL30754208 | 0.72 | DYRK1A (0.71) | MEN1KMT2A | |
| SCHEMBL30620440 | 0.72 | OGA (0.72) | OGA | |
| SCHEMBL26349079 | 0.72 | OGA (0.72) | OGA | |
| SCHEMBL20281964 | 0.70 | SMN1; SMN2 (0.74) | OGA | |
| SCHEMBL27022312 | 0.69 | OGA (1.00) | OGA | |
| SCHEMBL16112796 | 0.69 | OGA (0.71) | OGAKMT2A | |
| SCHEMBL16113448 | 0.69 | SMN1; SMN2 (0.76) | OGA | |
| SCHEMBL27008520 | 0.69 | OGA (0.77) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | OGA, OGT, ENGASE | OGA 1/4885MEN1 2839/4885KMT2A 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.